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Aim. Real-life evaluation in the management of patients aﬀected by macular edema secondary to retinal vein occlusion. Material
and Methods. A retrospective, observational study using the I-Macula Web platform. Results. Thirty-ﬁve patients (37 eyes; 15
females and 20 male) aﬀected by RVO were analysed. At 12 months, there was a statistically signiﬁcant improvement of best-
corrected visual acuity (p = 0 0235) and central macular thickness (p < 0 0001). The mean change in visual acuity was 8.9 letters.
Twenty-seven eyes underwent DEX implant (n = 62; mean: 2.29) only. Of these, 8, 4, 14, and 1 eyes underwent 1, 2, 3, and 4
DEX implants, respectively. The remaining 10 eyes were also injected with ranibizumab (n = 49; mean: 4.9). At 12 months, 12
eyes (32.5%) presented a dry macula, whereas the remaining 25 eyes (67.5%) still had macular edema. Mean interval between
the ﬁrst and second treatment (T1) and between the second and third treatment (T2) were 5.15 and (T2) 3.7 months,
respectively. Where only DEX implants were received, T1 and T2 was 5.1 and 4.9 months, respectively. Conclusions. This
study conﬁrms that DEX implants and/or anti-VEGF drugs improve visual acuity and central macular thickness in patients
aﬀected by RVO.
1. Introduction
In industrialised countries, retinal vein occlusion (RVO) is
the second most common vascular pathology after diabetic
retinopathy [1]. RVO, both central (CRVO) and branch
(BRVO), aﬀects the retina and causes loss of visual acuity.
In both CRVO and BRVO, macular edema is a major con-
tributor to loss of visual acuity. The onset of retinal ischemia
and iris neovascularization may, in time, lead to neovascular
glaucoma, especially where CRVO is the case [1]. Although
the pathogenesis of macular edema secondary to RVO is,
as yet, unclear, the production of anti-inﬂammatory cyto-
kines (prostaglandins and interleukin-6) and angiogenic fac-
tors as vascular endothelial growth (VEGF) and the
upregulation of tight junctional proteins resulting from the
hydrostatic eﬀects of venous hypertension appear to be the
keys [2, 3]. Major risk factors in RVO are systemic arterial
hypertension, hypercholesterolemia, diabetes mellitus, and
glaucoma [4].
Two classes of currently marketed drugs cater for the
treatment of post-RVO macular edema, that is, biodegrad-
able and slow-release implant of dexamethasone (Ozurdex,
Allergan) and anti-VEGF drugs ranibizumab (Lucentis,
Novartis) and aﬂibercept (Eylea, Bayer) [5–10].
The study aims to explore real-life and day-to-day
management of patients with macular edema secondary
to RVO treated with intravitreal treatment with dexameth-
asone (DEX) implant and/or anti-VEGF drugs in a real-
life setting. Clinical data were stored electronically on the
I-Macula Web platform, speciﬁcally designed for the
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management of patients with degenerative and vascular
retinal diseases [11].
2. Material and Methods
This retrospective, observational study was conducted at the
Medical Retinal Center of the University Eye Clinic of
Genova, Italy.
The following inclusion criteria were entered onto the
I-Macula Web platform:
(i) Diagnoses of macular edema secondary to RVO
(ii) Injection treatment with DEX implant and/or anti-
VEGF drugs
(iii) Last visit after at least a 12-month period of
treatment.
Standard procedures at this centre require that patients
diagnosed with RVO undergo the following tests: stan-
dardized best-corrected visual acuity (BCVA) performed
with Early Treatment for Diabetic Retinopathy Study
(ETDRS) charts, slit lamp biomicroscopy, tonometry, oph-
thalmoscopy, SD-OCT, and ﬂuorescein angiography.
BCVA, intraocular pressure, biomicroscopy, and SD-OCT
were repeated at follow-up visits. Retreatment criteria were
based basically on the presence of macular edema. In
order to have a real-life frame of the management of
RVO patients, the following variables were extracted by
the web platform:
(i) Mean age± standard deviation (SD), gender, and
follow-up (±SD);
(ii) Mean change in number of letters, intended as the
mean diﬀerence between the number of letters read
at baseline and at ﬁnal follow-up;
(iii) Mean change in central macular thickness (CMT),
intended as the mean diﬀerence between CMT at
baseline and at the ﬁnal follow-up;
(iv) Percentage of the eyes with an improved visual acu-
ity of ≥15 letters at the ﬁnal follow-up;
(v) Percentage of the eyes with loss of visual acuity of
≤15 letters at the ﬁnal follow-up;
(vi) Exposure to treatment regimen; mean number of
injections distinguished by drug type;
(vii) Mean time between diagnosis and the ﬁrst
treatment;
(viii) Average time between the ﬁrst and the second and
between the second and the third intravitreal injec-
tion of DEX;
(ix) Percentage of patients presenting macular edema at
the last follow-up visit;
(x) The correlation between macular edema at each
follow-up and the undertaken clinical decision.
2.1. Injective Treatment. Injective procedures were per-
formed in the operating room after topical anaesthesia with
benoxinate hydrochloride eye drops. The DEX implant
Table 1: Demography of 35 patients with macular edema secondary
to retinal vein occlusion.
Mean age (SD) 72 ±10.29
Follow-up (SD) 13.3 ±1.3
Gender
Female 15 42.8%
Male 20 57.2%
Bilateral 2 5.5%
CRVO 17 46.0%
BRVO 20 54.0%
Table 2: Distribution by age of 35 patients with macular edema
secondary to retinal vein occlusion.
Age (yrs) Patients %
40–49 2 5.7
50–59 2 5.7
60–69 9 25.7
70–79 14 40.0
Table 3: Number of letters at baseline and 12 months follow-up in
37 eyes with macular edema secondary to retinal vein occlusion
treated with DEX implant and/or ranibizumab.
RVO CRVO BRVO
Baseline 12 M Baseline 12 M Baseline 12 M
Mean
37.9
± 26
46.9
± 23
28.2
± 28
36.5
± 36
46.1
± 26
55.7
± 23
Min–Max 0–80 0–79 3–65 0–74 0–80 0–79
p 0.0235 0.1 0.09
Mean
change
8.9 8.3 9.5
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Figure 1: Number of letters at baseline and 12 months in 37 eyes
with macular edema secondary to retinal vein occlusion treated
with DEX implant and/or ranibizumab.
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Ozurdex® (Allergan) and the anti-VEGF ranibizumab
Lucentis® (Novartis) drugs were used for this study. Injec-
tions were performed 3.5–4mms from the limbus into the
lower temporal sector.
3. Results
Thirty-ﬁve patients (15 females and 20 males) of 37 eyes with
macular edema secondary to RVO were identiﬁed and ana-
lysed. Table 1 reports the demography of the selected study
population. Mean follow-up time was 13.3 months and mean
age was 72 years. Table 2 reports age-related distribution
across the sample. In 11.4% (n = 4) of the study population,
ages ranged between 40 and 59 years; the remaining 88.6%
(n = 31) was over 60 years.
Seventeen eyes presented CRVO and 20 presented
BRVO. Bilateral RVO occurred in two subjects. In both cases,
both the eyes were included in the study. Of the remaining
samples, 5 subjects presented other macular diseases in the
contralateral eye, and speciﬁcally, epiretinal membrane,
age-related macular degeneration, and pathological myopia
in 2, 2, and 1 eyes, respectively.
3.1. Visual Acuity. BCVA in terms of letters read was 37.9 and
46.9 at baseline and at 12 months, respectively (p = 0 0235;
paired t-test) (Table 3 and Figure 1). The mean change at 12
months was 8.9 letters. On the whole, 11 eyes (29.7%)
improvedmore than 15 letters, while 5 eyes (13.5%) worsened
by at least 15 letters at 12months.Within theCRVOor BRVO
cohorts, improvement in visual acuity was not statistically
signiﬁcant (Table 2), although themean change in the number
of letters was 8.3 and 9.5 in CRVO and BRVO, respectively.
3.2. Central Macular Thickness (CMT).Mean CMTwas 436.3
and 322.2 microns at baseline and at 12 months, respectively
(p < 0 0001; paired t-test) and the mean change of CMT at 12
months was −22.51 microns. Within the CVRO and BRVO
cohorts, CMT decrease was statistically signiﬁcant with a
mean diﬀerence of −151.6 and −87.86 microns, respectively
(Table 4 and Figure 2).
3.3. Exposure to Drugs and Administration Regimen.
Throughout the follow-up, a total of 111 intravitreal injec-
tions were administered for a mean of 2.36 injections per
eye (Table 5). DEX-based ﬁrst-line therapy was selected for
all the eyes. Of the 27 eyes injected solely with DEX implant
(n = 62; mean: 2.29), 8, 4, 14, and 1 eyes received 1, 2, 3, and 4
DEX implants, respectively (Figure 3). The remaining 10 eyes
also received ranibizumab (n = 49; mean: 4.9; Table 5). In this
subgroup, DEX was administered 15 times, and ranibizumab
was administered 34 times (Table 5).
On average, 13.35± 8.9 days occurred (range 0–30)
between diagnosis and the ﬁrst injection. Mean times
between the ﬁrst and second treatments (T1) and between
the second and third treatments (T2) were 5.15 months and
3.7 months, respectively. In the DEX implant cohort, T1
was 5.1 months and T2 was 4.9 months.
3.4. Anatomical Response and Therapeutic Decision-Making.
At 12 months, macular edema reabsorbed entirely in 12
eyes (32.5%), but persisted in the remaining 25 eyes
(67.5%). I-Macula Web was instrumental in establishing
whether or not a macular edema persisted at each exami-
nation and, if present, whether it had increased, decreased,
or remained unchanged compared to the previous exami-
nation. Data concerning the progression of macular edema
were taken into account and related to chosen therapeutic
plans. Where the macular edema had decreased, or was
absent, a clinician opted against treatment in 92.11% and
97.5% of cases, respectively. Where macular edema had
increased, treatment was selected in 66.67% of cases,
whereas where the condition had not changed, treatment
was repeated in 35.71% of cases only.
4. Discussion
This study shows that DEX implant and/or anti-VEGF-based
treatment led to statistically signiﬁcant improvements in
visual acuity and CMT in patients with macular edema sec-
ondary to RVO. With reference to variation in mean visual
acuity, results herein are in keeping with case series reported
in the literature. Indeed, Mayer et al. [12] reported on 36
patients treated with DEX implant. After 12 months, mean
variations of 6.6 and 7.8 letters were reported in CRVO and
BRVO, respectively, though no improvements of over 15 let-
ters are mentioned [12]. Again, whereas our study reports on
a cohort of 27 eyes receiving 62 DEX implants overall (mean:
2.9), Mayer et al. reported on a cohort of 38 eyes receiving 80
implants (mean: 2.1) [12]. In our case series, time intervals at
T1 and T2 in the subgroup receiving only DEX implant were
5.1 and 4.9 months, respectively, which appear to be in keep-
ing with results by Mayer et al. [12].
Our results conﬁrm that macular edema secondary to
RVO is a chronic disease requiring continuing, possibly
monthly, monitoring and cyclic injective retreatment. The
decision whether to treat or not is basically established by
the presence or absence of macular edema. However, it is well
known that it is not always possible to reproduce functional
Table 4: Central macular thickness at baseline and 12 months in 37 eyes with macular edema secondary to retinal vein occlusion treated with
DEX implant and/or ranibizumab.
RVO CRVO BRVO
Baseline 12 M Baseline 12 M Baseline 12 M
Mean 436.3± 135.5 322.2± 71.69 478.9± 151.5 342± 90.55 400.1± 111.5 312.2± 57.22
Min–Max 294.6–761.9 226.3–483.1 310.7–761.9 226.3–483.1 294.6–711.6 251.7–461
p <0.0001 <0.0043 <0.0072
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and anatomic results by a clinical trial in a real-life setting
due to the fact that population in a clinical trial is highly con-
trolled and selected. Interestingly, in 97.5% and 92.1% of our
cases, retreatment was ruled out whenever no edema was
detected or decreased compared to the previous examination.
When macular edema worsened, retreatment was prescribed
in 66% of cases; when the disease was stable, retreatment was
only prescribed in 35.7% of cases. It is unlikely that the
assessment of macular edema was incorrect since clinical
evaluations were carried out by trained ophthalmologists
with disease-speciﬁc experience. For this reason, the fact that
only 66% of the time has been given the indication to treat-
ment despite the increased macular edema means that the
clinical decision whether to treat or less is often aﬀected by
other factors such as patient compliance and waiting list.
The utility of such an electronic clinical platform such as
I-Macula Web to collect and analyse data proved to be useful
for the development of the study and to follow patients in a
real-life setting.
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Figure 2: Central macular thickness at baseline and 12months in 37
eyes with macular edema secondary to retinal vein occlusion treated
with DEX implant and/or ranibizumab.
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